NEXT GENERATION
nmCRPC

AR-V7 in Castration Resistant Prostate Cancer

by Emmanuel S. Antonarakis, MD | Mar 2018

Dr. Emmanuel Antonarakis provides an update on treating chemo-naive metastatic hormone sensitive prostate cancer and then discusses the impact of AR-V7 in castration resistant prostate cancer.

Keywords: AR-V7, Castration Resistant Prostate Cancer

ABOUT THE AUTHOR

Emmanuel S. Antonarakis, MD

Dr. Antonarakis is the Associate Director for Translational Research, and a Clark Endowed Professor of Medicine at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and Director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation (HOT).

About The Author

Emmanuel S. Antonarakis, MD

Dr. Antonarakis is the Associate Director for Translational Research, and a Clark Endowed Professor of Medicine at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and Director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation (HOT). He was formerly a Professor of Oncology and Urology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, as well as the Director of Prostate Cancer Medical Oncology Research and the Co-Director of the Prostate Cancer Multidisciplinary Clinic there. He graduated from the University of Wales College of Medicine (United Kingdom) in 2003, and then completed a Residency in Internal Medicine at Johns Hopkins Bayview Medical Center, followed by a Fellowship in Medical Oncology at Johns Hopkins Hospital. Since 2010, he has been on the Johns Hopkins faculty as an attending physician and translational researcher in the Department of Oncology. Dr. Antonarakis’ clinical interest is the management of prostate cancer and other genitourinary malignancies. His research focuses on drug development and clinical trial design for patients with prostate cancer, as well as cancer genomics. More specifically, he is interested in developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and cancer genomics to inform precision oncology approaches. He also has an interest in liquid biomarker development, specifically the clinical validation of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG-ACRIN), as well as the NCI Prostate Cancer Task Force and the NCCN Prostate Cancer Panel. He serves on the editorial boards of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 290 peer-reviewed articles and several book chapters, and has edited a textbook about AR signaling in cancer.

Join the GRU Community

- Why Join? -

Join the GRU Community

Watch, Listen, Learn, and Engage with Experts in the Urology Community.

You have Successfully Subscribed!

Share This

Chat with usLiveChat